Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial - Takeaways - MDSpire

Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial

  • By

  • Jinhong Zhu

  • Jinfeng Zhang

  • Xiaodong Ling

  • Changhong Wang

  • Yingnan Yang

  • Yangzhong Xin

  • Hao Jiang

  • Hao Liang

  • Luquan Zhang

  • Xionghai Qin

  • Jingle Lei

  • Chengyuan Fang

  • Xinxin Yang

  • Yuning Wang

  • Wei Meng

  • Xiaoyuan Wang

  • Hongxue Meng

  • Jianqun Ma

  • December 28, 2025

  • 0 min

Share

  • 1

    The study evaluates preoperative camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma.

  • 2

    This phase II trial aims to assess the safety, conversion efficacy, and survival benefits of the combination therapy in eligible patients.

  • 3

    Participants included patients with histologically confirmed locally advanced or advanced ESCC deemed unresectable by a multidisciplinary team.

  • 4

    The induction therapy regimen consisted of camrelizumab, paclitaxel, and nedaplatin administered every three weeks, with efficacy evaluations after two cycles.

  • 5

    The study follows CONSORT guidelines and aims to determine if this combination therapy can facilitate curative resection in initially unresectable ESCC.

Original Source(s)

Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial

  • by Jinhong Zhu, Jinfeng Zhang, Xiaodong Ling, Changhong Wang, Yingnan Yang, Yangzhong Xin, Hao Jiang, Hao Liang, Luquan Zhang, Xionghai Qin, Jingle Lei, Chengyuan Fang, Xinxin Yang, Yuning Wang, Wei Meng, Xiaoyuan Wang, Hongxue Meng, Jianqun Ma

  • December 28, 2025

Related Content

Comprehensive Bioinformatics Examination of Variations Between Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma

Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity

Clinical Features of Synchronous and Metachronous Superficial Esophageal Squamous Cell Carcinoma During Post-Endoscopic Submucosal Dissection Surveillance